A large proportion of children living with autism spectrum disorder also have recurrent constipation, diarrhoea, bloating and abdominal pain, and the behavioural difficulties that follow from them. Microbiota transfer therapy is aimed primarily at these digestive symptoms — under the direction of a treating physician, from a measurable baseline, with realistic expectations.
So we start not with a promise, but with numbers, limits and prices.
If you have found your way to us, this is probably not the first thing you have tried with your child. Many parents have already changed the diet, used food supplements and been given promises that did not work out. Meanwhile the same symptom patterns reappear every morning.
We do not make promises. We ask you to read what the numbers show, where the limits of the therapy lie, and what the first step costs. You then make the decision, together with your treating physician.
This is not a diagnosis and does not replace a medical examination — but in one minute it shows whether it is worth getting in touch with us.
If the child is immunosuppressed, is undergoing active oncological treatment or has a serious underlying illness; if there is an acute infection, fever or an unclarified abdominal condition — in these cases we currently cannot undertake to provide the capsules. If you are unsure which category you and your child fall into, ask for a telephone consultation and in 15 minutes we will talk the options through. If we see that we cannot help, we will say so honestly.
So that you know when things happen and where the decision points are.
Recording the patient's details, filling in the “Goals and expectations” questionnaire and, if you wish, a telephone consultation. Once the parent has made the decision, the compatibility test begins — and with it the microbiota transfer, since the test is itself a low-dose MTT. The therapy therefore does not start in week 10, but here.
We evaluate the test, select the appropriate LOT, fill in the exposome questionnaire together, and dose determination begins: with a biological trial we establish what quantity of the selected donation gives the most effective response. By now it becomes clear whether there is a capsule with which the body works properly, and it also shows what lifestyle changes will be needed. Decision: whether we move on to finding the dose density, so that MTT can start.
We determine the dose to be used. MTT has been running at a low dose since week 1; from here it continues at the therapeutic dose, and it is from this that real, continuous change in condition can be expected. By this point all the data are available. Decision: whether we move on to the minimum 60-day, full-dose phase with the capsule of the selected dose and LOT number.
Stability should be reached by now, and capsule use becomes an everyday routine. Decision: is further improvement expected from taking the capsules or from a change of LOT? If not, we begin tapering off: every 7–10 days we reduce the total number of capsules taken over two days by one.
The same sequence as on the timeline above. At every stage you will know what the next step is.
Fill in the form or ask for a call back. In a free, 15-minute conversation we clarify whether it makes sense to start in your child's case. If we see that it does not, we will say so.
→We will send you a link by e-mail with which you can register as a patient. At that point you will receive a unique identifier from us in P0000000 format. We record the patient's details, and you fill in the “Goals and expectations” questionnaire.
FindBiome is the compatibility test itself: it shows which donor your child's microbiome matches best. Since the capsule is a low-dose microbiota transfer, the therapy begins with this step. We assemble the capsules within 72 hours and they are ready for shipping. This is a paid step, but it does not commit you to continuing.
The week 5 we evaluate the test and select the appropriate LOT. Together we fill in the exposome questionnaire: we review lifestyle, nutrition and possible environmental exposures. Dose determination begins with a biological trial.
In week 10 we determine the dose to be used, and treatment continues at the full, therapeutic dose: a minimum 60-day phase with the capsule of the selected dose and LOT number.
The symptom diary and regular consultation accompany the whole process. By week 18 stability must be reached. If no further improvement is expected, we gradually taper the capsule off, reducing by one every 7–10 days.
You do not have to decide about the whole process at once. After every step you have the opportunity to assess the results achieved and to weigh up the potential change in condition.
| Step | What we provide | Price | Must you continue? |
|---|---|---|---|
| 1. Call back and pre-screening | A 15-minute conversation, clarifying suitability | free of charge | not |
| 2. FindBiome compatibility test 4×15 capsules | Testing donor–recipient matching, at the same time a low-dose MTT, the first phase of the therapy | 1.140 € + shipping cost | not |
| 3. Exposome consultation | Assessment of environmental and lifestyle exposures, shared goal-setting (with a DynaMAP baseline if required) | 185 € the DynaMAP can be ordered separately: €325 (professional) or €575 (comprehensive) | not |
| 4. TransferBiome course 60 / 3×60 capsules | Personalised composition, full protocol + follow-up (the quantity prescribed is decided during the biological trial) | €1,350 / 60 capsules | – |
| Item | Included? |
|---|---|
| Call back and pre-screening (15-minute conversation) | yes — free of charge |
| FindBiome compatibility test | separate item: 1,140 € |
| Exposome consultation | separate item: €185 |
| DynaMAP microbiome profile | can be ordered separately: €325 (professional) or €575 (comprehensive) |
| Appearing in person | is not necessary — the process is remote throughout |
| The capsules in the packaging unit ordered | yes — at the price in the table above |
| Shipping cost | not — the delivery charge is separate |
| Follow-up during the course | yes |
| Joint closing assessment and tapering-off plan | yes |
| Examination by the treating physician, laboratory tests | not — these take place at your own healthcare provider |
The same high-quality donor microbiota, processed in a certified laboratory — in two steps, tailored to your situation.
The data are strongest for the digestive symptoms. The 2025 systematic review found symptom reductions of 35–82% in the uncontrolled studies, and the longest follow-up measured a symptom score 58% lower even two years after treatment.126, 123
For the behavioural symptoms the data are contradictory. In the two controlled studies to date, no significant difference was demonstrated on the primary endpoint in either case; improvement appears more consistently on the parent- and clinician-rated scales. The uncontrolled studies show a more favourable picture, but they carry a high risk of bias.124, 125
The safety data are reassuring, but not flawless. No serious adverse event has so far been reported in children; in the double-blind trial, however, somewhat more adverse events occurred in the treated arm (23% vs. 14%).126, 124 The treatment does not cure autism.
Among people living with autism spectrum disorder and ADHD, gut dysbiosis[G] — an upset in the balance of the gut flora, also known as the gut microbiota — and the digestive symptoms that accompany it are often seen: bloating, constipation or diarrhoea. These complaints reduce quality of life in themselves, but at the same time, through the gut–brain axis the gut microbiota is also closely linked to the central nervous system.
A schematic diagram of the main pathways described so far; on the metabolic pathway, for example, short-chain fatty acids act as signalling molecules. The existence of the connection is well documented; how far changing the microbiota modifies the behavioural symptoms is still an open question.
Microbiota transfer therapy (MTT) — commonly known as faecal transplantation — works by introducing gut microbiota from a thoroughly screened, healthy donor in capsule form, in order to restore the disturbed balance. As far as we know today it does not cure autism or ADHD, and it cannot be used in the same way in everyone affected. For more detail, the Microbiota Guide and the Microbiota Handbook are worth reading.
And what about ADHD? An important distinction: the studies cited above were, without exception, carried out in children living with autism spectrum disorder. Clinical data on ADHD are essentially unavailable. If a persistent digestive complaint accompanies ADHD, we can consider the request on an individual basis — but here we can say even less about the behavioural symptoms.
Every donor goes through our DSQ donor screening framework.
Every capsule we ship carries a LOT number (a manufacturing batch identifier), so it can be traced back to the donor at any time.
The compatibility test performed with FindBiome shows even before the therapeutic dose is used whether there is a matching donation.
We do not start a protocol without a treating physician. The capsule is in every case prescribed by the treating physician.
The symptom diary is used throughout the full 6–8 month protocol, with follow-up consultations: this is how it becomes clear how your child responds to the transfer.
No serious adverse event occurred in the clinical trials; mild, transient complaints did (diarrhoea, abdominal discomfort, slightly raised temperature).
The exposome is the totality of environmental exposures acting across a whole lifetime: nutrition, toxin burden, antibiotic use, stress, sleep quality and general lifestyle all continuously shape the gut microbiota and the signalling it mediates through the gut–brain axis. We are convinced that the state of the microbiota cannot be interpreted separately from the genetic background and environmental factors.
That is why an integral part of the process is a targeted exposome consultation: we map lifestyle, eating habits and possible toxin burden, then, if required, supplement this with DynaMAP profiling; this gives the measurable baseline against which later results can be compared. To help you rethink nutrition, our Foods database is also a help.
We have summarised what is worth knowing before the decision — the numbers, their limits, the eligibility criteria and the decision points of the process — and attached a symptom diary covering two weeks. Filling in the diary is useful in itself: it gives a more accurate picture of your child's complaints, and if you start later, it becomes the baseline. You can also take it with you to your treating physician.
If you are a treating physician, or the parent asks you for an opinion: treatment follows the MTT Clinical Protocol Guide v7.1 which sets out patient selection, dose determination, the rules of escalation and gradual tapering, donor screening requirements and the follow-up steps — everything you need for the decision at the bedside. Referring a patient requires no separate agreement: a single message is enough and we will initiate the professional consultation.
Clinical Protocol Guide v7.1 (PDF)Professional consultation →
Write and tell us what you are struggling with. We will look at whether it makes sense to start in your child's case — and if we see that it does not, we will say so.
MicroBiome Bank does not sell products; it connects donors and recipients by providing professional medical services: it organises the recruitment of donors and their screening in a certified laboratory, the stool tests, and the processing of the screened donation into capsule form. The contents of the capsules remain the property of the donor until the recipient has paid in full. The brand names of the services serve to make them easier to remember. It is important to emphasise that in autism and ADHD, microbiota transfer therapy can offer support only in certain forms and with individual responses — it is not a cure. We deliver the capsules “to the doctor's hand”, and they are to be used under the guidance of a treating physician. For detailed information, please contact us.
The MicroBiome Bank service is not a substitute for professional medical advice, diagnosis or treatment. The decision to use it rests in every case with the treating physician.